(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.


1. Class of shares acquired:
Common stock of the Company
2. Total number of shares acquired:
3. Aggregate amount of acquisition cost:
1,675,924,400 yen
4. Date of acquisition:
July 31, 2017
5. Method of acquisition:
Purchased on the Tokyo Stock Exchange


1. Details of the resolution at the meeting of the Board of Directors (announced on July 28, 2017)

- Class of shares to be acquired:
Common stock of the Company
- Total number of shares to be acquired:
Up to 50 million shares
(The percentage compared to the total
   number of shares outstanding: 2.42%)
- Aggregate amount of acquisition cost:
Up to 70 billion yen
- Period of acquisition:
From July 31, 2017 to October 31, 2017

2. Accumulated Company’s own shares acquired through July 31, 2017, pursuant to the above board resolution

- Total number of shares acquired:
- Aggregate amount of acquisition cost:
1,675,924,400 yen

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)